EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden

G Tskhvarashvili, K Aher, I Sveide, U Katus, A Westerlund, F Hoti, C Wennerström, F Hassan, J Lee, C Hermanrud, I Johnsson, A Passey und 4 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20198 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von G Tskhvarashvili und 15 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology and Database Studies, IQVIA, Tallinn, Estonia. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Plaque psoriasis (PsO) requires long‐term treatment for symptom control and remission; thus, a long‐term pharmacological intervention is necessary. Treatment persistence reflects long‐term therapeutic effectiveness and tolerance.

Objectives

This study investigates drug persistence and compares treatment discontinuation rates across biologic agents and apremilast used by PsO patients in Finland and Sweden.

Methods

This retrospective register‐based cohort study included bio‐naïve patients (≥18 years) with moderate‐to‐severe PsO, who initiated treatment with abatacept, adalimumab, brodalumab, certolizumab pegol, etanercept, golimumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab or apremilast during 2008–2020 in Finland or Sweden. The main analysis evaluated persistence (based on duration of continuous treatment) and compared rates of treatment discontinuation using guselkumab as reference drug, during 2018–2020 in Finland. Treatment discontinuation was assessed by survival analysis of the time to first drug discontinuation, including switching to other study drugs. Due to limited sample size ( n < 20), certain biologics (abatacept, brodalumab, certolizumab pegol, etanercept, golimumab, risankizumab and tildrakizumab) were excluded from the persistence analysis.

Results

In Finland, 709 patients fulfilled the inclusion criteria during 2018–2020 for the main analysis. The highest persistence was observed for guselkumab and ustekinumab with 90 and 85% of treated patients, respectively, continuing treatment for ≥1 year. Comparable results were observed in the expanded cohort analysis (index starting in 2008; 2745 bio‐naïve patients in Finland and 10,970 in Sweden). Furthermore, patients treated with guselkumab in Finland showed lower treatment discontinuation rates compared to other study drugs.

Conclusion

Guselkumab and ustekinumab demonstrated high persistence as measured by continued treatment for at least 1 year. Furthermore, these treatments demonstrated lower rates of discontinuation compared to other study drugs included in the analysis. Understanding the balance between efficacy and feasibility in treatment decisions is crucial, as feasibility may impact persistency outcomes and potentially increase persistency rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsHumansRetrospective StudiesMaleFinlandFemaleSwedenMiddle AgedRegistriesAdultSeverity of Illness IndexAgedAntibodies, Monoclonal, HumanizedThalidomide

Substanzen

Biological ProductsAntibodies, Monoclonal, HumanizedapremilastThalidomide

Autor:innen und Institutionen

  • Epidemiology and Database Studies, IQVIA, Tallinn, Estonia.
  • Biostatistics, IQVIA, Tallinn, Estonia.
  • Biostatistics, IQVIA, Mölndal, Sweden.
  • Epidemiology and Database Studies, IQVIA, Tartu, Estonia.
  • Epidemiology and Database Studies, IQVIA, Solna, Sweden.
  • Biostatistics, IQVIA, Espoo, Finland.

Zitieren

APA

Tskhvarashvili, G., Aher, K., Sveide, I., Katus, U., Westerlund, A., Hoti, F., Wennerström, C., Hassan, F., Lee, J., Hermanrud, C., Johnsson, I., Passey, A., Nissinen, R., Polesie, S., Mälkönen, T., & Saarelainen, L. (2025). Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20198

Vancouver

Tskhvarashvili G, Aher K, Sveide I, Katus U, Westerlund A, Hoti F, et al. Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20198

BibTeX
@article{Tskhvarashvili2025,
  author = {Tskhvarashvili, G and Aher, K and Sveide, I and Katus, U and Westerlund, A and Hoti, F and Wennerström, C and Hassan, F and Lee, J and Hermanrud, C and Johnsson, I and Passey, A and Nissinen, R and Polesie, S and Mälkönen, T and Saarelainen, L},
  title = {Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20198}
}
Kostenlos starten →